Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial

Quantifying change in individual subjects affected by frontotemporal lobar degeneration using automated longitudinal MRI volumetry

(2011) Lars Frings et al.   HUMAN BRAIN MAPPING

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

(2011) Juan Manuel Domínguez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MRI measurements predict PSP in unclassifiable parkinsonisms: A cohort study

(2011) M. Morelli et al.   NEUROLOGY

Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: Determining sample size for treatment trials

(2011) Jennifer L. Whitwell et al.   PARKINSONISM & RELATED DISORDERS

MRI Substudy Participation in Alzheimer Disease (AD) Clinical Trials

(2010) Rema Raman et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Rational therapeutic approaches to progressive supranuclear palsy

(2010) M. Stamelou et al.   BRAIN

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

(2009) L. Serenó et al.   NEUROBIOLOGY OF DISEASE

Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures

(2009) Hans-Jürgen Huppertz et al.   NEUROIMAGE

MR Imaging Index for Differentiation of Progressive Supranuclear Palsy from Parkinson Disease and the Parkinson Variant of Multiple System Atrophy

(2007) Aldo Quattrone et al.   RADIOLOGY